Skip to main content

Menomune A/C/Y/W-135 Side Effects

Generic name: meningococcal polysaccharide vaccine

Medically reviewed by Last updated on Dec 15, 2021.

Note: This document contains side effect information about meningococcal polysaccharide vaccine. Some dosage forms listed on this page may not apply to the brand name Menomune A/C/Y/W-135.

Applies to meningococcal polysaccharide vaccine: parenteral solution for im use.

Side effects include:

MenACWY-D (Menactra®): Injection site reactions (e.g., pain, induration, erythema, swelling), headache, fatigue, malaise, arthralgia, diarrhea, anorexia, chills, fever, vomiting, rash. Most common adverse effects in those 11 through 55 years of age after a booster dose were injection site pain and myalgia; overall rates of solicited local and systemic reactions similar to those observed after a primary dose.

MenACWY-CRM (Menveo®): Injection site reactions (tenderness, erythema), irritability, sleepiness, persistent crying, change in eating habits, vomiting, diarrhea in infants 2 through 23 months of age; injection site reactions (pain, erythema, induration), irritability, sleepiness, malaise, headache in children 2 through 10 years of age; injection site pain, headache, myalgia, malaise, nausea in adults and adolescents. Most common adverse effects after a booster dose in those 15 through 55 years of age were injection site pain and fatigue.

MenACWY-TT (MenQuadfi®): Injection site reactions (e.g., pain, erythema, swelling), myalgia, headache, malaise. Most common adverse effects after a booster dose in those ≥15 years of age were injection site pain, myalgia, and malaise; overall rates of solicited local and systemic reactions similar to those observed after a primary dose.

For Healthcare Professionals

Applies to meningococcal polysaccharide vaccine: subcutaneous powder for injection.


The most common adverse events were injection site pain, headache, irritability, and diarrhea.[Ref]


Very common (10% or more): Injection site pain (48.1%), injection site redness (16%), injection site induration (11%), injection site tenderness

Common (1% to 10%): Injection site swelling, injection site hematoma

Uncommon (0.1% to 1%): Injection site reaction

Rare (less than 0.1%): Severe local reactions

Postmarketing reports: Extensive limb swelling at the injection site (frequently associated with erythema, sometimes involving the adjacent joint or swelling of the entire injected limb)[Ref]

Nervous system

Very common (10% or more): Headache (41.8%), drowsiness (11.2%)

Uncommon (0.1% to 1%): Hypoesthesia, dizziness

Very rare (less than 0.01%): Somnolence, neurological reactions

Postmarketing reports: Vasovagal syncope, paresthesia, Guillain-Barre syndrome[Ref]


Very common (10% or more): Fatigue (32.3%), malaise (22.3%), fever

Common (1% to 10%): Chills, febrile reactions (>38C)

Postmarketing reports: Asthenia, influenza-like symptoms[Ref]


Very common (10% or more): Irritability (12.2%)

Uncommon (0.1% to 1%): Insomnia, crying[Ref]


Very common (10% or more): Arthralgia (16%)

Uncommon (0.1% to 1%): Myalgia, pain in extremity

Postmarketing reports: Musculoskeletal stiffness[Ref]


Very common (10% or more): Appetite lost

Common (1% to 10%): Anorexia

Postmarketing reports: Decreased appetite[Ref]


Very common (10% or more): Diarrhea (14%)

Common (1% to 10%): Vomiting, nausea[Ref]


Common (1% to 10%): Rash

Uncommon (0.1% to 1%): Pruritus

Rare (less than 0.1%): Urticaria, angioedema

Postmarketing reports: Angioneurotic edema[Ref]


Very common (10% or more): Local axillary lymphadenopathy[Ref]


Postmarketing reports: Hypersensitivity (such as rash, urticaria, pruritus, dyspnea, angioedema), allergic reactions (including anaphylactic and anaphylactoid reactions)[Ref]


Uncommon (0.1% to 1%): Upper respiratory tract illness

Rare (less than 0.1%): Wheeze[Ref]


Postmarketing reports: IgA nephropathy[Ref]

More about Menomune A/C/Y/W-135 (meningococcal polysaccharide vaccine)

Professional resources

Related treatment guides


1. Cerner Multum, Inc. UK Summary of Product Characteristics.

2. Cerner Multum, Inc. Australian Product Information.

3. Product Information. Menomune (meningococcal polysaccharide vaccine). Sanofi Pasteur Limited. 2015.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.